Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 38Carcinoma, Non-Small-Cell Lung 23Stomach Neoplasms 19Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 18Esophageal Squamous Cell Carcinoma 17Esophageal Neoplasms 16Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 8Sarcoma 6Recurrence 6Neoplasm Metastasis 6Melanoma 6Liver Neoplasms 6Cholangiocarcinoma 6Lung Neoplasms 5Hodgkin Disease 5Biliary Tract Neoplasms 5Osteosarcoma 4Neoplasms 4Locally Advanced Gastric Cancer 4Advanced Gastric Cancer 4Rectal Neoplasms 3Nasopharyngeal Neoplasms 3Glioblastoma 3Gestational Trophoblastic Disease 3Urinary Bladder Neoplasms 2

Interventions

camrelizumab 1Tumor Burden 1Radiation 1Pyloromyotomy 1Itraconazole 1Esophagectomy 1Erlotinib Hydrochloride 1Botulinum Toxins, Type A 1Blood Specimen Collection 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophageal Diseases × camrelizumab × Clear all
NCT03187314 2020-08-17

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Hangzhou Cancer Hospital

Phase 2 Completed
25 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Diseases, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡